The 1032nd NESACS Meeting jointly with
the 2024 Medicinal Chemistry Symposium
“New Drugs on the Horizon”

3:00 pm
Welcome
Raj Rajur, Medicinal Chemistry Program Chair
CreaGen, Woburn, MA

3:10 pm
Introductory Remarks (Moderator)
Paul Scola
BMS, Cambridge, MA

3:15 pm – 4:00 pm
Denise Grünenfelder, Ph.D.
BMS, Cambridge, MA
Title: “Discovery of BMS-986408: A dual inhibitor of Diacylglycerol kinases alpha and zeta for cancer therapy”

4:00 pm – 4:45 pm
Ben Milgram, Ph.D.
Scorpion Therapeutics, Cambridge, MA
Title: “Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR Exon20 Insertion Inhibitor for the Treatment of Non-Small-Cell Lung Cancer”

4:45 pm – 5:00 pm
Break

5:00 pm – 5:45 pm
Kevin J. Filipski, Ph.D.
Pfizer, Cambridge, MA
Title: “PF-07328948, the first BDK inhibitor/degrader clinical candidate as a treatment for heart failure”

5:45 pm – 6:30 pm
Robin Fairhurst, Ph.D.
Novartis, Basel, CH
Title: “Discovery of NVP-DFF332 as an Inhibitor of the Transcription Factor Hypoxia-Inducible Factor-2ALPHA (HIF-2α)”

7:00 pm – 8:30 pm
Dinner

Organizing Committee:
Mark Ashwell; Brian. Aquila; Blaise Lippa; Andrew Scholte; Peter Fuller; Michelle Lamb; Silvana Leit; Melissa Grenier-Davies; Paul Scola; Lauren Monovich; Jason Beiger; Paul Greenspan; Raj Rajur

Registration and more details at: https://2024_Med_Chem_Symposium_and_October_Meeting.eventbrite.com